前列腺癌根治术后淋巴结阳性患者的前列腺床与盆腔淋巴结放疗:PLATIN-4和PLATIN-5前瞻性试验的长期结果
本研究纳入2009至2018年间78例根治性前列腺切除术后淋巴结复发患者,分别接受前列腺床(PLATIN-4)或盆腔淋巴结作为野衔接(PLATIN-5)的挽救性放疗联合雄激素剥夺治疗。两项试验均无治疗中断,24个月随访时晚期3级及以上泌尿生殖和胃肠道毒性发生率为4%。
要点
- 两项试验均无因毒性导致的治疗中断。
- PLATIN-4中位总生存未达到,PLATIN-5为117个月。
- 24个月随访时晚期3级及以上泌尿生殖和胃肠道毒性发生率为4%。
核心结论
- 前列腺床和盆腔淋巴引流区挽救性放疗联合长期雄激素剥夺治疗是根治性前列腺切除术后淋巴结阳性前列腺癌的可治愈性治疗选择,野内疾病控制极佳。
- 前列腺床放疗后以盆腔淋巴结作为野衔接的放疗在长期生存方面可行,且无高级别毒性。
研究设计与样本
- 前瞻性PLATIN-4和PLATIN-5试验,2009年至2018年间纳入78例根治性前列腺切除术后淋巴结复发患者。
- PLATIN-4试验患者接受前列腺床推量放疗,PLATIN-5试验患者接受累及淋巴结推量并以盆腔淋巴结作为野衔接放疗。
- 放疗前2个月开始雄激素剥夺治疗,推荐持续24个月。
主要发现
- 两项试验均未报告治疗中断。
- PLATIN-4中位总生存未达到,PLATIN-5中位总生存为117个月。
- PLATIN-4中位无进展生存为66个月,PLATIN-5中位无进展生存为39个月。
- 24个月随访时,4%的患者观察到晚期3级及以上泌尿生殖和胃肠道毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: After radical prostatectomy (RP), adjuvant or salvage radiation treatment in node-positive prostate cancer is offered to prevent systemic disease. Prospective long-term survival and toxicity data on patients with radiation for nodal disease are still scarce. This study evaluates safety and feasibility of salvage radiation therapy to the pelvic lymph nodes in node-positive prostate cancer after RP. METHODS AND MATERIALS: Between 2009 and 2018, 78 patients with lymph node recurrence after RP (PLATIN-4 trial) or after RP and prostate bed radiation therapy (PLATIN-5 trial) were treated with salvage pelvic lymph node radiation therapy with boost to the involved nodes as field abutment (PLATIN-5) and boost to the prostate bed (PLATIN-4). Androgen deprivation therapy was started 2 months before radiation and recommended for 24 months. The primary endpoint was safety and feasibility of the intensity modulated radiation therapy-image guided radiation therapy technique based on the rate of treatment discontinuations and incidence of Common Terminology Criteria for Adverse Events grade 3+ toxicity. Secondary endpoints were progression-free survival and overall survival. RESULTS: No treatment discontinuations were reported in either trial. Median overall survival was not reached in PLATIN-4 and was 117 months in PLATIN-5. Median progression-free survival was 66 months in PLATIN-4 and 39 months in PLATIN-5. Late grade 3+ genitourinary and gastrointestinal toxicities were observed in 4% of patients at 24 months of follow-up. CONCLUSIONS: Salvage radiation therapy to the prostate bed and pelvic lymphatic drainage combined with long-term androgen deprivation therapy is a curative treatment option for patients with node-positive prostate cancer after RP, with excellent in-field disease control. Pelvic lymph node radiation therapy as field abutment after prostate bed radiation therapy is feasible with long-term survival and no high-grade toxicity.
引用
- Fink CA, Wegener D, Sauer LD, et al. Pelvic Irradiation for Node-Positive Prostate Cancer After Prostatectomy: Long-Term Results of the Prospective PLATIN-4 and PLATIN-5 Trials. Int J Radiat Oncol Biol Phys. 2023. PMID: 37863242. doi:10.1016/j.ijrobp.2023.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。